Rivernorth Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Rivernorth Capital Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3M	Sell	150,000 -48,730	-25%	-$861K	0.14%	210
2026 Q1	$3.23M	Hold	198,730	–	–	0.16%	183
2025 Q4	$3.33M	Sell	198,730 -108,907	-35%	-$1.83M	0.16%	194
2025 Q3	$4.77M	Buy	307,637 +77,793	+34%	+$1.07M	0.27%	98
2025 Q2	$2.94M	Buy	229,844 +67,161	+41%	+$828K	0.16%	168
2025 Q1	$2.06M	Buy	162,683 +122,869	+309%	+$1.66M	0.11%	168
2024 Q4	$522K	Buy	+39,814	New	+$574K	0.03%	206

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Rivernorth Capital Management's HQL Position: Q2 2026 in Review

Rivernorth Capital Management reduced its abrdn Life Sciences Investors (HQL) stake by 25% in Q2 2026, selling an estimated $861K and leaving 150,000 shares worth $3M. The position accounts for 0.14% of the portfolio, ranked #210.

Rivernorth Capital Management first reported a position in HQL in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.77M in Q3 2025. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Rivernorth Capital Management held 150,000 shares of abrdn Life Sciences Investors worth $3M as of Q2 2026.
Rivernorth Capital Management sold 48,730 abrdn Life Sciences Investors shares in Q2 2026, an estimated $861K.
abrdn Life Sciences Investors made up 0.14% of Rivernorth Capital Management's portfolio in Q2 2026, its #210 holding.
Rivernorth Capital Management first reported a position in abrdn Life Sciences Investors in Q4 2024 and has held it in 7 quarters since.
Rivernorth Capital Management's abrdn Life Sciences Investors position peaked at $4.77M in Q3 2025.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Rivernorth Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.